TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38606105

Group type: EXPERIMENTAL
Intervention: DNAJB1-PRKACA fusion-based neoepitope vaccine Fusion-VAC-XS15 combined with anti-PD-L1 antibody atezolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-PD-L1 antibody atezolizumab
Number of subjects: 0
Study: 38606174

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication reconciliation
Number of subjects: 414

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 414
Study: 38606196

Group type: EXPERIMENTAL
Intervention: van Cittert iterative deconvolution (VC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-compartment PVC method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-compartment PVC method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: region-based voxelwise PVC method
Number of subjects: 0

Group type: COMPARATOR
Intervention: non-PVC images
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LMEM-derived %ΔSUVR values
Number of subjects: 0
Study: 38606277

Group type: EXPERIMENTAL
Intervention: Magnesium-rich artificial cerebrospinal fluid (MACSF)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: MACSF
Number of subjects: 71

Group type: COMPARATOR
Intervention: NS
Number of subjects: 71
Study: 38606384

Group type: EXPERIMENTAL
Intervention: 200 mg TU twice daily with meals, titrated to between 100 and 800 mg TU daily
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: KYZATREX™
Number of subjects: 155
Study: 38606412

Group type: EXPERIMENTAL
Intervention: Learning Through Play plus Culturally adapted Cognitive Behaviour Therapy (LTP+CaCBT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both groups (LTP+CaCBT and PE)
Number of subjects: 130
Study: 38606524

Group type: EXPERIMENTAL
Intervention: NT-proBNP monitoring (n=79)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (n=78)
Number of subjects: 157
Study: 38606621

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) titration during DISE
Number of subjects: 25
Study: 38606776

Group type: EXPERIMENTAL
Intervention: SingHypertension intervention (clinician training, subsidized medications, nurse-delivered motivational conversations, telephone follow-ups)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SingHypertension intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 38606777

Group type: EXPERIMENTAL
Intervention: Apilimod dimesylate 125 mg twice daily for 12 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 38606958

Group type: EXPERIMENTAL
Intervention: RSVpreF (240 µg with or without aluminum hydroxide)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 38607238

Group type: EXPERIMENTAL
Intervention: Higher frequency or longer duration of daytime nap
Number of subjects: 3069

Group type: COMPARATOR
Intervention: Naps
Number of subjects: 3069
Study: 38607276

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38607410

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 326
Study: 38607494

Group type: EXPERIMENTAL
Intervention: Lifestyle modification intervention
Number of subjects: 578

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 578
Study: 38607515

Group type: EXPERIMENTAL
Intervention: mHealth intervention (digital tools, lessons, adaptive goals, tailored feedback, text messages, Facebook prompts)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 280
Study: 38607538

Group type: EXPERIMENTAL
Intervention: pembrolizumab-chemotherapy
Number of subjects: 141

Group type: COMPARATOR
Intervention: placebo-chemotherapy
Number of subjects: 141
Study: 38607628

Group type: EXPERIMENTAL
Intervention: Coaching intervention (6 sessions over 3 months)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control condition (standard institutional resources)
Number of subjects: 138
Study: 38608150

Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy (HAIP-SYS)
Number of subjects: 31
Study: 38608217

Group type: EXPERIMENTAL
Intervention: Brucellosis patients with osteoarthritis
Number of subjects: 429

Group type: COMPARATOR
Intervention: Patients without osteoarthritis
Number of subjects: 429
Study: 38608236

Group type: EXPERIMENTAL
Intervention: Acute Flower Cannabis Use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Edible Cannabis Use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38608658

Group type: EXPERIMENTAL
Intervention: Pirfenidone (escalated from 3×1 to 3×3 capsules of 267 mg/day within 3 weeks for 12 months)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 51
Study: 38608691

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy (240 mg every 2 weeks)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO3 plus IPI1: 3 mg/kg every 2 weeks plus 1 mg/kg every 6 weeks)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO1 plus IPI3: 1 mg/kg every 3 weeks plus 3 mg/kg every 3 weeks for four cycles then nivolumab 240 mg every 2 weeks)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (pooled NIVO1 plus IPI3)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO3 plus IPI1)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO1 plus IPI3)
Number of subjects: 176
Study: 38608693

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg/day
Number of subjects: 17
Study: 38608694

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg daily
Number of subjects: 18
Study: 38608752

Group type: EXPERIMENTAL
Intervention: WOOP+MOVE! or TeleMOVE!
Number of subjects: 0

Group type: COMPARATOR
Intervention: MOVE!/TeleMOVE! alone (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (MOVE! or TeleMOVE!)
Number of subjects: 0
Study: 38608871

Group type: EXPERIMENTAL
Intervention: Diversity of foods purchased
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Production diversity (among nonbreastfed children)
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Household food purchase and food production diversities
Number of subjects: 586
Study: 38609174

Group type: EXPERIMENTAL
Intervention: EMBOVAC aspiration catheter
Number of subjects: 100
Study: 38609315

Group type: EXPERIMENTAL
Intervention: Health education intervention on influenza vaccination
Number of subjects: 3036

Group type: COMPARATOR
Intervention: Routine health education (Control)
Number of subjects: 3036
Study: 38609316

Group type: EXPERIMENTAL
Intervention: Elotuzumab administered starting on day 4 post-ASCT and then every 28 days until 1 year post-ASCT, combined with autologous lymphocyte infusion and lenalidomide maintenance (cycles 4-12).
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Elotuzumab and autologous lymphocyte infusion post-ASCT.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Correlative analysis of immune microenvironment post-ASCT.
Number of subjects: 15
Study: 38609322

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg two times per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg two times per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNF inhibitors (TNFi)
Number of subjects: 0
Study: 38609522

Group type: EXPERIMENTAL
Intervention: Web-based decision aid (DA) entitled RealRisks
Number of subjects: 50
Study: 38609684

Group type: EXPERIMENTAL
Intervention: Remimazolam-based total intravenous anesthesia
Number of subjects: 96

Group type: COMPARATOR
Intervention: Desflurane-based inhalational anesthesia
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 96
Study: 38609723

Group type: EXPERIMENTAL
Intervention: Knowledge-based Clinical Decision Support System (CDSS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (Clinician recommendations)
Number of subjects: 37
Study: 38609737

Group type: EXPERIMENTAL
Intervention: Strict 6-month wheat-free diet (WFD)
Number of subjects: 201
Study: 38609987

Group type: EXPERIMENTAL
Intervention: Maytenus senegalensis (800 mg every 8 hours for 4 days)
Number of subjects: 12
Study: 38609994

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 302
Study: 38610004

Group type: EXPERIMENTAL
Intervention: Intrathecal idursulfase (idursulfase-IT)
Number of subjects: 56
Study: 38610005

Group type: EXPERIMENTAL
Intervention: Ear-EEG assessment of spike frequency in patients with AD
Number of subjects: 24

Group type: COMPARATOR
Intervention: Arterial spin-labelling MRI (ASL-MRI) measurement of rCBF in the hippocampus
Number of subjects: 24
Study: 38610031

Group type: EXPERIMENTAL
Intervention: Pamiparib 40 mg twice daily every 3 weeks for up to 1 year or until disease progression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pamiparib
Number of subjects: 0
Study: 38610034

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with ProPrems® (Bifidobacterium infantis, Bifidobacterium lactis, and Streptococcus thermophilus) diluted in 3 mL breastmilk per day until gestational week 34
Number of subjects: 1620

Group type: COMPARATOR
Intervention: Placebo (0.5 g maltodextrin powder) diluted in 3 mL breastmilk per day until gestational week 34
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 1620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1620
Study: 38610138

Group type: EXPERIMENTAL
Intervention: Staff-facilitated telemedicine model for HCV treatment initiation
Number of subjects: 0
Study: 38610925

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant systemic therapy (NAS) with immunotherapy (anti-PD-1, combination anti-CTLA-4 and anti-PD-1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab as NAS therapy (3 doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ipilimumab + nivolumab as NAS therapy
Number of subjects: 0
Study: 38610950

Group type: EXPERIMENTAL
Intervention: 5% Imiquimod (IMQ) applied three times a week for 16 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: sHLA-G levels in CIN before starting IMQ application
Number of subjects: 43
Study: 38610966

Group type: EXPERIMENTAL
Intervention: Asciminib (STAMP inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dasatinib and Ponatinib (ATP site inhibitors)
Number of subjects: 0
Study: 38611082

Group type: EXPERIMENTAL
Intervention: Transperineal Laser Ablation (TPLA) treatment, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38611586

Group type: EXPERIMENTAL
Intervention: Caucasian women
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Women aged <35 years
Number of subjects: 408

Group type: COMPARATOR
Intervention: Total study population
Number of subjects: 408
Study: 38611595

Group type: EXPERIMENTAL
Intervention: Metabolomic analysis at diagnosis (D0)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Metabolomic analysis at end of induction treatment (D33)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Comparison between common B-ALL and pre-B ALL
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Comparison between D0 and D33
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 38611689

Group type: EXPERIMENTAL
Intervention: Pulmonary Embolism Severity Index (PESI) calculated and reported in clinical record form on top of standard of care; experimental arm.
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard of care; control arm.
Number of subjects: 118
Study: 38613023

Group type: EXPERIMENTAL
Intervention: Microalgae extract containing fucoxanthin for 12 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Microalgae extract containing fucoxanthin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 37
Study: 38613092

Group type: EXPERIMENTAL
Intervention: Prolonged fasting (3-12 days, <600 kcal/d)
Number of subjects: 176
Study: 38613322

Group type: EXPERIMENTAL
Intervention: Perioperative immunonutrition (IMN) with oral supplementation enriched with arginine, omega-3 fatty acids, and dietary nucleotides (Group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Preoperative immunonutrition (IMN) followed by standard isocaloric nutrition (Group 1)
Number of subjects: 50
Study: 38613329

Group type: EXPERIMENTAL
Intervention: anti-EGFR (Group A: panitumumab)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: anti-EGFR (Group B: cetuximab)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: anti-VEGF (Group C: bevacizumab and aflibercept)
Number of subjects: 588
Study: 38613372

Group type: EXPERIMENTAL
Intervention: CHORUS™ app access (intervention)
Number of subjects: 267

Group type: COMPARATOR
Intervention: No app use (control)
Number of subjects: 267
Study: 38613420

Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses (ortho-k)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Single-vision spectacles (SVS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cognitive interviewing
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rasch analysis
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Danish version of PREP2
Number of subjects: 75
Study: 38613425

Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg once daily
Number of subjects: 64
Study: 38613545

Group type: EXPERIMENTAL
Intervention: Flecainide acetate oral inhalation solution (FlecIH), single dose administered via oral inhalation over 8 minutes in a supervised medical setting.
Number of subjects: 98
Study: 38613579

Group type: EXPERIMENTAL
Intervention: Balanced medial-lateral wall orbital decompression (BMLW-OD)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Selective 3-wall decompression (S3W-OD)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Both groups (BMLW-OD and S3W-OD)
Number of subjects: 57
Study: 38613938

Group type: EXPERIMENTAL
Intervention: High PPI (> 1.5)
Number of subjects: 741

Group type: COMPARATOR
Intervention: Low PPI (< 1.5) and Low Hb (< 9.7 g/dL)
Number of subjects: 741
Study: 38614026

Group type: EXPERIMENTAL
Intervention: Machine learning method for predicting neurocognitive outcomes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current clinical practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: State-of-the-art method in label ranking
Number of subjects: 0
Study: 38614240

Group type: EXPERIMENTAL
Intervention: Prime Diet Quality Score (PDQS) calculated from dietary data obtained from food frequency questionnaire, PrimeScreen, and 24-h recall.
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Prime Diet Quality Score (PDQS)
Number of subjects: 1460
Study: 38614279

Group type: EXPERIMENTAL
Intervention: 60 Gy in 8 fractions (stereotactic body radiation therapy)
Number of subjects: 30
Study: 38614365

Group type: EXPERIMENTAL
Intervention: Emergency Medical Services (EMS) transport
Number of subjects: 26305

Group type: COMPARATOR
Intervention: Self-transport
Number of subjects: 26305
Study: 38614372

Group type: EXPERIMENTAL
Intervention: 7T MRI assessment of hippocampal subfield volumes in AD patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: UDSNB3.0 cognitive scores in AD patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Volume of Dentate Gyrus (DG) in AD patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CA1 volume in AD patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: DG volume in AD patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CA1 and Tail volumes in AD patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 7T MRI as a diagnostic tool
Number of subjects: 24
Study: 38614379

Group type: EXPERIMENTAL
Intervention: Computerized Wobble Board Exercise Training (CWBET)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Training (CSET)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 51
Study: 38614445

Group type: EXPERIMENTAL
Intervention: Telehealth Oncofertility Care (TOC) intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 20
Study: 38614447

Group type: EXPERIMENTAL
Intervention: bCBCT augmented with intranasal oxytocin (40 international units administered 30 min before each session)
Number of subjects: 120

Group type: COMPARATOR
Intervention: bCBCT plus placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: bCBCT augmented with intranasal oxytocin
Number of subjects: 120
Study: 38614630

Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) stove, continuous fuel delivery, and behavioural messaging
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Usual cooking with biomass
Number of subjects: 3200
Study: 38614631

Group type: EXPERIMENTAL
Intervention: Euvichol-S (two 1.5 mL doses)
Number of subjects: 2529

Group type: COMPARATOR
Intervention: Shanchol (active control)
Number of subjects: 2529

Group type: EXPERIMENTAL
Intervention: Euvichol-S
Number of subjects: 2529

Group type: COMPARATOR
Intervention: Shanchol
Number of subjects: 2529
Study: 38614954

Group type: EXPERIMENTAL
Intervention: TBE vaccine (0.5-mL for adults, 0.25-mL for pediatric) administered at 3 visits.
Number of subjects: 165
Study: 38615067

Group type: EXPERIMENTAL
Intervention: Letermovir 480 mg daily orally for 28 weeks
Number of subjects: 22
Study: 38615070

Group type: EXPERIMENTAL
Intervention: Seasonal vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unvaccinated uninfected children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children infected after seasonal vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline hemagglutination antibody inhibition
Number of subjects: 0
Study: 38615472

Group type: EXPERIMENTAL
Intervention: Temozolomide 75 mg/m² given every other week (one week on/one week off)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Temozolomide 75 mg/m²
Number of subjects: 38
Study: 38615657

Group type: EXPERIMENTAL
Intervention: pegcetacoplan
Number of subjects: 10

Group type: COMPARATOR
Intervention: eculizumab
Number of subjects: 10
Study: 38615662

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 210
Study: 38615673

Group type: EXPERIMENTAL
Intervention: Intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112, and a mucosal recall with either placebo or CTH522 topical ocularly at day 140 (Group A)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112 with additional topical ocular administration of CTH522 (Group B)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112 with additional intradermal administration of CTH522 (Group C)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intramuscular 15 μg CTH522-CAF01, two boosters at day 28 and 112 (Group D)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intramuscular 85 μg CTH522-CAF09b, two boosters at day 28 and 112 (Group E)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Intramuscular placebo (Group F)
Number of subjects: 65
Study: 38615750

Group type: EXPERIMENTAL
Intervention: Patient navigation program delivered remotely by a trained lay-person from a community-based organization.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care control.
Number of subjects: 0
Study: 38615899

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET), 16-week, twice-weekly, whole-body intervention
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 10
Study: 38616018

Group type: EXPERIMENTAL
Intervention: Healthy older adults
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Older adults with COPD
Number of subjects: 227

Group type: COMPARATOR
Intervention: Overall comparison between healthy and COPD groups
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 227
Study: 38616241

Group type: EXPERIMENTAL
Intervention: Valoctocogene roxaparvovec
Number of subjects: 294

Group type: COMPARATOR
Intervention: Prophylactic factor VIII (FVIII)
Number of subjects: 294
Study: 38616242

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) - four cycles of 5 min of pressurization (about 200 mmHg) and 5 min of rest in the 3 days before and 7 days after surgery.
Number of subjects: 648

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 648
Study: 38616276

Group type: EXPERIMENTAL
Intervention: Quality improvement collaborative across 10 UK sites
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team (MDT) discussions
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Quality assessment of long covid services
Number of subjects: 50
Study: 38616275

Group type: EXPERIMENTAL
Intervention: Portable pedal machines (PPMs) for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal-desk (control group)
Number of subjects: 40
Study: 38616308

Group type: EXPERIMENTAL
Intervention: Dasatinib plus low-intensity chemotherapy for one month followed by dasatinib monotherapy for two months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dasatinib-based low-intensity chemotherapy
Number of subjects: 22
Study: 38616411

Group type: EXPERIMENTAL
Intervention: BPL-003 (5-methoxy-DMT) at doses of 1-12 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: BPL-003 (5-methoxy-DMT) at doses of 10 and 12 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: BPL-003 (5-methoxy-DMT)
Number of subjects: 44
Study: 38616438

Group type: EXPERIMENTAL
Intervention: RSVpreF vaccine (120-µg injection)
Number of subjects: 992
Study: 38616564

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000